Gilead Sciences, Inc. GILD and partner Merck MRK announced positive data from two late-stage studies, ISLEND-1 and ISLEND-2, ...
Clinical Trials Arena on MSN
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials
Gilead and MSD will be filing the data from the Phase III trials of the once-weekly HIV pill to regulatory authorities.
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV ...
Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...
Gilead Sciences Inc. and Merck & Co. said an experimental long acting pill combining two HIV medicines had met its primary ...
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed.
German biotech Tubulis has shared updated data from a phase 1 study of the antibody-drug conjugate (ADC) TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront in A | ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study ...
Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results